Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).

被引：13
|
作者：
Reardon, David A.
De Groot, John Frederick
Colman, Howard
Jordan, Justin T.
Daras, Mariza
Clarke, Jennifer Leigh
Nghiemphu, Phioanh Leia
Gaffey, Sarah C.
Peters, Katherine B.
机构：
[1] Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Hunstman Canc Inst Utah, Salt Lake City, UT USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Calif Los Angeles, Los Angeles, CA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2010
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
    Ahluwalia, Manmeet Singh
    Rauf, Yasmeen
    Li, Hong
    Wen, Patrick Y.
    Peereboom, David M.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] New approach in delivering chemotherapy: Locoregional treatment for recurrent glioblastoma (rGBM)
    Boiardi, A
    Eoli, M
    Salmaggi, A
    Lamperti, E
    Botturi, A
    Broggi, G
    Bartolomei, M
    Silvani, A
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (04) : 123 - 127
  • [33] A RETROSPECTIVE STUDY EVALUATING THE SAFETY AND SURVIVAL OF THE COMBINATION OF PD-1 IMMUNE CHECKPOINT BLOCKADE AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
    Friedman, Joshua
    Hormigo, Adilia
    NEURO-ONCOLOGY, 2019, 21 : 5 - 5
  • [34] PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DOSE-DENSE TEMOZOLOMIDE IN PATIENTS WITH RECURRENT GLIOBLASTOMA: PRELIMINARY SAFETY ANALYSIS
    Sepulveda, Juan
    Belda, Cristobal
    Balana, Carmen
    Perez Segura, Pedro
    Reynes, Gaspar
    Gil, Miquel
    Gallego, Oscar
    Berrocal, Alfonso
    NEURO-ONCOLOGY, 2011, 13 : 55 - 55
  • [35] Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
    Liu, Zhiguang
    Zhang, Guanqun
    Zhu, Liang
    Wang, Jiangbo
    Liu, Dongbo
    Lian, Lifei
    Liu, Jianlin
    Lai, Tianbao
    Zhuang, Xiaorong
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [36] Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
    Lee, Eudocia Q.
    Reardon, David A.
    Schiff, David
    Drappatz, Jan
    Muzikansky, Alona
    Grimm, Sean A.
    Norden, Andrew D.
    Nayak, Lakshmi
    Beroukhim, Rameen
    Rinne, Mikael L.
    Chi, Andrew S.
    Batchelor, Tracy T.
    Hempfling, Kelly
    McCluskey, Christine
    Smith, Katrina H.
    Gaffey, Sarah C.
    Wrigley, Brendan
    Ligon, Keith L.
    Raizer, Jeffrey J.
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2015, 17 (06) : 862 - 867
  • [37] Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
    Bota, D. A.
    Eroglu, Z.
    Reardon, D. A.
    Fu, B. D.
    Norfleet, J.
    Desjardins, A.
    Linskey, M. E.
    Peters, K.
    Friedman, H. S.
    Vredenburgh, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Phase II Study of Bevacizumab and Temsirolimus Combination Therapy for Recurrent Glioblastoma Multiforme
    Lassen, Ulrik
    Sorensen, Morten
    Gaziel, Tine Bernhardtsen
    Hasselbalch, Benedikte
    Poulsen, Hans Skovgaard
    ANTICANCER RESEARCH, 2013, 33 (04) : 1657 - 1660
  • [39] A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (NDGBM OR RGBM)
    Wen, Patrick
    Odia, Yazmin
    Mehta, Minesh
    Goldlust, Samuel
    Tamir, Sharon
    Shacham, Sharon
    Wang, Hongwei
    Sheehan, Heidi
    Li, Kai
    NEURO-ONCOLOGY, 2020, 22 : 195 - 195
  • [40] Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer A Phase 2 Nonrandomized Clinical Trial
    Zsiros, Emese
    Lynam, Sarah
    Attwood, Kristopher M.
    Wang, Chong
    Chilakapati, Shanmuga
    Gomez, Eduardo Cortes
    Liu, Song
    Akers, Stacey
    Lele, Shashikant
    Frederick, Peter J.
    Odunsi, Kunle
    JAMA ONCOLOGY, 2021, 7 (01) : 78 - 85
12345